english.prescrire.org > Spotlight > Archives : 2022 > In the October issue of Prescrire International: Trastuzumab deruxtecan (Enhertu°) in HER2-positive metastatic breast cancer

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2022 : 1 | 30 | 60

In the October issue of Prescrire International: Trastuzumab deruxtecan (Enhertu°) in HER2-positive metastatic breast cancer

FREE DOWNLOAD Evaluation of trastuzumab deruxtecan (Enhertu°), authorised for treatment of some inoperable or metastatic breast cancers, was mainly based on one non-comparative trial, with a primary endpoint that is not necessarily objective.
Full text available for free download.

Prescrire's rating

  •  NOTHING NEW  Given the lack of any comparative evaluation, trastuzumab deruxtecan has not been shown to extend survival after failure of several cancer drugs in patients with HER2-positive metastatic breast cancer. Trastuzumab deruxtecan carries a risk of potentially serious adverse effects, in particular interstitial lung disease, which is sometimes fatal. 

EDITORS' OPINION
The magic of words
It is sometimes difficult to determine if a new cancer drug represents a therapeutic advance for patients, because its evaluation has been based solely on surrogate, not clinical, endpoints. This is the case, for example, with trastuzumab deruxtecan (Enhertu°), authorised for treatment of some inoperable or metastatic breast cancers...

Full text available for free download below.

 ©Prescrire 1 October 2022

Source: "Trastuzumab deruxtecan (Enhertu°) in HER2-positive metastatic breast cancer" Prescrire International 2022; 31 (241): 239. Free.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter


See also:

Numerous other texts
available via the "Search"
function, using the keyword
"trastuzumab"
Search


Read more:

All the subjects in
Prescrire's Spotlight
Free >